Skip to content
NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP

Quoin Pharmaceuticals Ltd. QNRX

7 fiscal years on record · USD · FY2025 reported · SEC filings only
$-15.8M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Growth

·
Revenue, FY2025 · full 7-year series below
Revenue $M Net income $M
FY2021 · Revenue 0.0 · Net income -21.5
-10M-20M
201920222025
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

·
ROE
FY2025 · ROE -141.6%
-100%-200%
201920222025
Three returns, three denominators.
Return on capital employedNot available: we don't have a clean operating profit figure for this period.

Each USD of equity lost 142 cents this year.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks

Total assetsUSD 20.4M
EquityUSD 13.1M
CashUSD 3.8M
Current ratio3.61×

Equity funds 64% of total assets.

The 7-year record

7 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
QNRX, 7-year financial record
Metric 2025202420232022202120202019
Revenue $B◌◌◌◌0.00.00.0
Operating income $B−0.0−0.0◌◌◌◌◌
EBITDA $B◌◌◌◌◌◌◌
Income tax $B◌◌◌◌◌◌◌
Net income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EPS, diluted $◌−1.91−9.64−46.81−67.96−0.70−0.52
Dividend / sh $◌◌◌◌◌◌◌
Payout % — not applicable: no dividend———————
ROE %−141.6−120.6−132.9−232.7———
Shares out B0.050.010.000.000.000.000.00

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 20 reconciliationsAUDITED

Reconciled in 7 of the 7 fiscal years we could check. 26 checks were skipped: the balance sheet is not tagged before 2020. 12 checks were skipped: EPS is not tagged before 2019.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inoutside the United States — SEC code L3
Fiscal year endsnot stated in the filings
SEC categorysmaller reporting company
Data on record since2018

Share this section

Download image